Trial Profile
A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms PLANETCD
- Sponsors Celltrion
- 17 Oct 2023 Results comparing discontinuation rates due to lack of efficacy during maintenance treatment with infliximab or vedolizumab in patients with Crohn'S Disease (NCT02883452, NOR-SWITCH, PLANETCD, and LIBERTY-CD) infliximab and two RCTs (GEMINI 2 and VISIBLE 2) on vedolizumab, presented at the 31st United European Gastroenterology Week.
- 01 Jul 2022 Results of pooled analysis from NCT01369329, NCT02425111, NCT02096861 and other study comparing the efficacy of adalimumab, infliximab, ustekinumab, and vedolizumab on the ability to achieve endoscopic healing (EH) after 1 year of therapy in moderate-severe Crohns disease, published in the American Journal of Gastroenterology
- 23 May 2021 Results of post-hoc and pooled analysis from NCT01369329, NCT01369342, NCT01369355 and NCT02096861 developing validate a modified multiplier of the SES-CD (MM-SES-CD) as a Predictior of Endoscopic Remission in Crohns Disease, presented at the Digestive Disease Week 2021